Collaboration between patient organisations and pharma companies: insights from Poland
Abstract
Background: Collaboration between patient organisations and pharmaceutical companies plays an increasing role in public health governance, shaping advocacy agendas and priority-setting. While these partnerships provide essential resources, they also raise concerns about conflicts of interest and industry influence. Existing research has focused mainly on Western contexts, with limited evidence from post-communist countries.
Methods: This qualitative study is based on in-depth interviews with leaders of patient organisations in Poland. Interviews explore funding structures, initiation of cooperation, decision-making processes, everyday practices, perceived benefits and risks, and approaches to transparency and conflict of interest. Data are analysed using thematic analysis.
Results: Preliminary findings indicate that patient organisations rely on pharmaceutical industry funding while simultaneously recognising the controversies associated with such collaboration. Organisations develop diverse strategies to manage potential conflicts of interest. These approaches vary considerably between organisations. Findings also suggest that transparency is inconsistently understood and often undervalued as a tool for addressing conflict of interest.
Conclusions: This study provides one of the first qualitative insights into industry–patient organisation relationships in a Central and Eastern European context. The findings contribute to ongoing debates on transparency and governance, offering evidence relevant for policy and regulatory discussions.
Key messages: • This study reveals how patient organisations in Poland navigate collaboration with the pharmaceutical industry, highlighting varied strategies to manage conflicts of interest and ensure independence.
• Findings highlight gaps in transparency and governance, offering evidence to inform policies that strengthen accountability in patient organisation–industry collaboration.
Related
- Multiregional characterisation of collaboration between clinical and community-based organisations for postpartum transition care delivery: A mixed methods study protocol.
- Immersion 360, a european patient-partnered research project aimed at developing communication skills in paediatrics and raising awareness of interprofessional collaboration practice in partnership.
- Rethinking primary-palliative care collaboration: insights from a mixed-methods study in a spanish region.
- Novel variant and enteroendocrine hormone deficiency in a patient with proline and glutamate‐rich protein with a coiled coil domain 1 (PERCC1) associated enteropathy: New diagnostic and therapeutic insights
- Comprehensive Genomic Profiling of Relapsed Interdigitating Dendritic Cell Sarcoma Reveals Novel Molecular Insights in a Patient Achieving Durable Remission After Autologous Stem Cell Transplantation
BibTeX
@article{sacharczukpawlowska2026collaboration,
title = {{Collaboration between patient organisations and pharma companies: insights from Poland}},
author = {K Sacharczuk-Pawłowska and P Ozierański and G Makowski and M Makowska},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1916},
url = {https://doi.org/10.1093/eurpub/ckag169.1916},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Collaboration between patient organisations and pharma companies: insights from Poland
AU - K Sacharczuk-Pawłowska
AU - P Ozierański
AU - G Makowski
AU - M Makowska
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1916
UR - https://doi.org/10.1093/eurpub/ckag169.1916
AB - Background: Collaboration between patient organisations and pharmaceutical companies plays an increasing role in public health governance, shaping advocacy agendas and priority-setting. While these partnerships provide essential resources, they also raise concerns about conflicts of interest and industry influence. Existing research has focused mainly on Western contexts, with limited evidence from post-communist countries. Methods: This qualitative study is based on in-depth interviews with leaders of patient organisations in Poland. Interviews explore funding structures, initiation of cooperation, decision-making processes, everyday practices, perceived benefits and risks, and approaches to transparency and conflict of interest. Data are analysed using thematic analysis. Results: Preliminary findings indicate that patient organisations rely on pharmaceutical industry funding while simultaneously recognising the controversies associated with such collaboration. Organisations develop diverse strategies to manage potential conflicts of interest. These approaches vary considerably between organisations. Findings also suggest that transparency is inconsistently understood and often undervalued as a tool for addressing conflict of interest. Conclusions: This study provides one of the first qualitative insights into industry–patient organisation relationships in a Central and Eastern European context. The findings contribute to ongoing debates on transparency and governance, offering evidence relevant for policy and regulatory discussions. Key messages: • This study reveals how patient organisations in Poland navigate collaboration with the pharmaceutical industry, highlighting varied strategies to manage conflicts of interest and ensure independence. • Findings highlight gaps in transparency and governance, offering evidence to inform policies that strengthen accountability in patient organisation–industry collaboration.
SN - 1101-1262
SN - 1464-360X
ER -